Canadian company developing oral COVID-19 vaccine
Canadian company is developing oral COVID-19 vaccine, first batch of clinical trials start. A biotechnology company located in Burnaby, BC, Canada, has begun human trials on an oral COVID-19 vaccine it has developed, and preliminary test data is expected to be announced early next year （Canadian Metropolis Net）
According to the regional newspaper Burnaby Now, Symvivo announced on Friday that the first batch of healthy volunteers have signed up for clinical trials in Australia to evaluate the safety and tolerability of its bacTRL-Spike oral vaccine candidate in preventing infection with COVID-19 pneumonia Sexuality and immunogenicity.
The company said that, unlike traditional vaccines that are injected intramuscularly, bacTRL-Spike is an oral vaccine that provides the general public with the possibility of self-administered vaccines without the help of professional medical staff.
The company’s chief medical officer, Eric Sievers, said, “We are very pleased that volunteers have started taking our oral DNA COVID-19 vaccine. At the same time, we are also continuing to expand and carry out production activities for future clinical development. The rapidly spreading The epidemic requires innovative scientific methods. We believe that safe and protective oral vaccines may change the status quo of traditional vaccination methods without the need for syringes, needles and trained vaccinators.”
The first phase of the trial is currently being carried out in cooperation with Brisbane, Australia and Nucleus Network. Associate Professor Paul Nriffin, an infectious disease physician and microbiologist at Nucleus Network, is the main person in charge of the project. This test will evaluate the safety and preliminary evidence for the immunogenicity of SARS CoV-2 triggered by bacTRL-Spike in healthy volunteers. The preliminary data is expected to be released in early 2021.
Symvivo announced in October that it has received up to 2.8 million yuan in consulting services and funding from the Federal Government’s National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical development of bacTRL-Spike.
Before receiving the funding, Symvivo received a notification from the Canadian government that the relevant agencies had reviewed Symvivo’s proposal and its bacTRL-Spike vaccine candidate had reached the funding threshold required for technological products.